Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women - The Women's Health Initiative: A Randomized Trial

JAMA

Volumn 289, Issue 20, 2003, Pages 2673-2684

  Wassertheil Smoller, Sylvia ^a   Hendrix, Susan L ^b   Limacher, Marian ^c   Heiss, Gerardo ^d   Kooperberg, Charles ^e   Baird, Alison ^f   Kotchen, Theodore ^g   Curb, J David ^h   Black, Henry ⁱ   Rossouw, Jacques E ^j   Aragaki, Aaron ^e   Safford, Monika ^k   Stein, Evan ^l   Laowattana, Somchai ^m   Mysiw, W Jerry ⁿ  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h Hawaii Department of Health   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^k UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^l Pharmaceutical Product Development   (United States)

^m Georgetown's McDonough School Georgetown Institute   (United States)

ⁿ OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ASCORBIC ACID; BIOLOGICAL MARKER; ESTROGEN; GESTAGEN; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEMATOCRIT; HUMAN; HYPERTENSION; INFLAMMATION; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; SMOKING; STROKE; THROMBOSIS; VITAMIN SUPPLEMENTATION; BLOOD; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; ESTROGEN THERAPY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

AGED; BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE CONGENERS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0037534909     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.20.2673     Document Type: Article

References (52)

1. Bousser MG. Stroke in women: the 1997 Paul Dudley White International Lecture. Circulation. 1999; 99:463-7.
2. Bonita R. Epidemiology of stroke. Lancet. 1992; 339:342-344.
3. Murphy SL. Deaths: final data for 1998. Natl Vital Stat Rep. 2000;48:1-105.
4. Design of the Women's Health Initiative clinical trial and observational study: the Women's Health Initiative Study Group. Control Clin Trials. 1998;19:61-109.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33.
6. Gillum LA, Mamidipudi SK, Johnston SC, Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000;284:72-78.
7. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280: 605-613.
8. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
9. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103:638-642.
10. Hart CL, Hole DJ, Smith GD. Risk factors and 20-year stroke mortality in men and women in the Renfrew/Paisley study in Scotland. Stroke. 1999;30:1999-2007.
11. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA. 1988;259: 1025-1029.
12. Whisnant JP. Modeling of risk factors for ischemic stroke: the Willis Lecture. Stroke. 1997;28:1840-1844.
13. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA. 1999;281:1112-1120.
14. Inzitari D, Eliasziw M, Gates P, et al, for the North American Symptomatic Carotid Endarterectomy Trial Collaborators. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. N Engl J Med. 2000;342:1693-700.
15. Barnett HJ, Gunton RW, Eliasziw M, et al. Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. JAMA. 2000;283:1429-1436.
16. Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol. 1999;84:1018-1022.
17. Makris TK, Stavroulakis GA, Krespi PG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens. 2000;13:783-788.
18. Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999;19:1986-1991.
19. Mustonen P, Lepantalo M, Lassila R. Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis. Arterioscler Thromb Vasc Biol. 1998;18:244-249.
20. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med. 1997;337: 356]. N Engl J Med. 1997;336:973-979.
21. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med. 1997;337: 356]. N Engl J Med. 1997;336:973-979.
22. Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation. Circulation. 2000;102:191-196.
23. Lip GY, Lip PL, Zarifis J, et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: effects of introducing ultra-low-dose warfarin and aspirin. Circulation. 1996;94:425-431.
24. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb. 1994;14:1829-1836.
25. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
26. Adams HP Jr, Bendixen BH, Kappelle LJ, et al, for TOAST Trial of Org 10172 in Acute Stroke Treatment. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke. 1993;24:35-41.
27. Goldstein LB, Jones MR, Matchar DB, et al. Improving the reliability of stroke subgroup classification using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. Stroke. 2001;32:1091-1098.
28. Madden KP, Karanjia PN, Adams HP Jr, Clarke WR. Accuracy of initial stroke subtype diagnosis in the TOAST study: Trial of ORG 10172 in Acute Stroke Treatment. Neurology. 1995;45:1975-1979.
29. Lindley RI, Warlow CP, Wardlaw JM, Dennis MS, Slattery J, Sandercock PA. Interobserver reliability of a clinical classification of acute cerebral infarction. Stroke. 1993;24:1801-1804.
30. Jennett B, Snoek J, Bond MR, Brooks N. Disability after severe head injury: observations on the use of the Glasgow Outcome Scale. J Neurol Neurosurg Psychiatry. 1981;44:285-293.
31. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480-484.
32. Ainsworth BE, Haskell WL, Leon A. Compendium of physical activities: classification of energy costs of human activities. Med Sci Sports Exerc. 1993;25:71-80.
33. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication: The Framingham Study. Stroke. 1994; 25:40-43.
34. Steiner P, Freidl J, Bremner W, Stein E. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the lipid clinics' methodology. J Clin Chem. 1981;19:850.
35. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res. 1978;19:65-76.
36. Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
37. Vu Dac N, Mezdour H, Parra HJ, Luc G, Luyeye I, Fruchart JC. A selective bi-site immunoenzymatic procedure for human Lp(a) lipoprotein quantification using monoclonal antibodies against apo[a] and apoB. J Lipid Res. 1989;30:1437-1443.
38. Russell WG. Measurement and clinical significance of high-density lipoprotein cholesterol subclasses. In: Rifai-Warnick, ed. Laboratory Measurement of Lipids, Lipoproteins, and Apolipoproteins; 1994:207-222.
39. Paganini-Hill A. Estrogen replacement therapy and stroke. Prog Cardiovasc Dis. 1995;38:223-242.
40. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ. 1988;297:519-522.
41. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol. 1990;97:1080-1086.
42. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users: results from a national cohort. Arch Intern Med. 1993;153:73-79.
43. Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke: follow-up of a population-based cohort in Sweden. Arch Intern Med. 1993;153: 1201-1209.
44. Petitti DB, Sidney S, Quesenberry CP Jr, Bernstein A. Ischemic stroke and use of estrogen and estrogen/progestogen as hormone replacement therapy. Stroke. 1998;29:23-28.
45. Pedersen AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet. 1997;350:1277-1283.
46. Boysen G, Nyboe J, Appleyard M, et al. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke. 1988;19:1345-1353.
47. Lemaitre RN, Heckbert SR, Psaty BM, Smith NL, Kaplan RC, Longstreth WT Jr. Hormone replacement therapy and associated risk of stroke in postmenopausal women. Arch Intern Med. 2002;162:1954-1960.
48. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med. 1985;313:1038-1043.
49. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872-281.
50. Hurn PD, Macrae IM. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab. 2000; 20:631-652.
51. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.
52. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.